Results 101 to 110 of about 24,275 (247)

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18:Nuclear hormone receptors [PDF]

, 2017
The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and ...
,, Alexander, Stephen Ph, Cidlowski, John A, Davies, Jamie A, Faccenda, Elena, Harding, Simon D, Kelly, Eamonn, Marrion, Neil V, Pawson, Adam J, Peters, John A, Sharman, Joanna L, Southan, Christopher   +11 more
core   +5 more sources

Bile acid metabolism and sleep: Mechanistic interplay and clinical implications of the gut–liver–brain axis

Sleep Research, EarlyView.
Abstract The bidirectional interplay between sleep and metabolic homeostasis is fundamental to physiological health. While the roles of glucose and lipid metabolism in sleep regulation have been extensively characterized, bile acids (BAs), which are traditionally viewed as digestive surfactants, are emerging as critical metabolic messengers with ...
Yu Jiang, Shuangyan Li, Dhirendra Paudel, Miaoqin Tan, Bin Zhang   +4 more
wiley   +1 more source

Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats.

PLoS ONE, 2017
IntroductionThe farnesoid X receptor (FXR) is abundantly expressed in the ileum, where it exerts an enteroprotective role as a key regulator of intestinal innate immunity and homeostasis, as shown in pre-clinical models of inflammatory bowel disease ...
Laurens J Ceulemans, Len Verbeke, Jean-Paul Decuypere, Ricard Farré, Gert De Hertogh, Kaatje Lenaerts, Ina Jochmans, Diethard Monbaliu, Frederik Nevens, Jan Tack, Wim Laleman, Jacques Pirenne   +11 more
doaj   +1 more source

Farnesoid X receptor: A “homeostat” for hepatic nutrient metabolism

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2018
The Farnesoid X receptor (FXR) is a nuclear receptor activated by bile acids (BAs). BAs are amphipathic molecules that serve as fat solubilizers in the intestine under postprandial conditions. In the post-absorptive state, BAs bind FXR in the hepatocytes, which in turn provides feedback signals on BA synthesis and transport and regulates lipid, glucose
Vittoria, Massafra, Saskia W C, van Mil
openaire   +2 more sources

Disordered Bile Acid Metabolism in Alcohol‐Related Hepatitis

Alimentary Pharmacology &Therapeutics, EarlyView.
Serum conjugated primary bile acids accumulate in alcohol‐related hepatitis due to downregulation of hepatocyte bile acid transporters. Hepatocyte growth factor is elevated in alcohol‐related hepatitis and downregulates BSEP expression. This detrimentally affects the hepatoprotective adaptive reduction in NTCP/increase in BSEP seen in cholestasis ...
Luke D. Tyson, Stephen Atkinson, Benjamin H. Mullish, Alexandros Pechlivanis, Michael Allison, Andrew Austin, Katie Chappell, Stuart J. Forbes, Ewan H. Forrest, Alastair M. Kilpatrick, Tong Liu, Laura Martinez‐Gili, Steven Masson, Mark J. W. McPhail, Joao Nunes, Paul Richardson, Daniel Rodrigo‐Torres, Stephen D. Ryder, Mark Wright, Vishal C. Patel, Nikhil Vergis, Elaine Holmes, Mark R. Thursz   +22 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2015/16:Nuclear hormone receptors [PDF]

, 2015
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org),
Aldrich, R, Alexander, SPH, Attali, B, Back, M, Barnes, NM, Bathgate, R, Beart, PM, Becirovic, E, Benson, HE, Biel, M, Birdsall, NJ, Boison, D, Brauner-Osborne, H, Broeer, S, Bryant, C, Burnstock, G, Burris, T, Cain, D, Calo, G, Chan, SL, Chandy, KG, Chiang, N, Christakos, S, Christopoulos, A, Chun, JJ, Chung, J-J, Cidlowski, JA, Clapham, DE, Connor, MA, Coons, L, Cox, HM, Dautzenberg, FM, Davies, JA, Dent, G, Douglas, SD, Dubocovich, ML, Edwards, DP, Faccenda, E, Farndale, R, Fong, TM, Forrest, D, Fowler, CJ, Fuller, P, Gainetdinov, RR, Gershengorn, MA, Goldin, A, Goldstein, SAN, Grimm, SL, Grissmer, S, Gundlach, AL, Hagenbuch, B, Hammond, JR, Hancox, JC, Hartig, S, Hauger, RL, Hay, DL, Hebert, T, Hollenberg, AN, Holliday, ND, Hoyer, D, Ijzerman, AP, Inui, KI, Ishii, S, Jacobson, KA, Jan, LY, Jarvis, GE, Jensen, R, Jetten, A, Jockers, R, Kaczmarek, LK, Kanai, Y, Kang, HS, Karnik, S, Kelly, E, Kerr, ID, Korach, KS, Lange, CA, Larhammar, D, Leeb-Lundberg, F, Leurs, R, Lolait, SJ, Macewan, D, Maguire, JJ, Marrion, N, May, JM, Mazella, J, McArdle, CA, McDonnell, DP, Michel, MC, Miller, LJ, Mitolo, V, Monie, T, Monk, PN, Mouillac, B, Murphy, PM, Nahon, J-L, Nerbonne, J, Nichols, CG, Norel, X, Oakley, R, Offermanns, S, Palmer, LG, Panaro, MA, Pawson, AJ, Perez-Reyes, E, Pertwee, RG, Peters, JA, Pike, JW, Pin, JP, Pintor, S, Plant, LD, Poyner, DR, Prossnitz, ER, Pyne, S, Ren, D, Richer, JK, Rondard, P, Ross, RA, Sackin, H, Safi, R, Sanguinetti, MC, Sartorius, CA, Segaloff, DL, Sharman, JL, Sladek, FM, Southan, C, Stewart, G, Stoddart, LA, Striessnig, J, Summers, RJ, Takeda, Y, Tetel, M, Toll, L, Trimmer, JS, Tsai, M-J, Tsai, SY, Tucker, S, Usdin, TB, Vilargada, J-P, Vore, M, Ward, DT, Waxman, SG, Webb, P, Wei, AD, Weigel, N, Willars, GB, Winrow, C, Wong, SS, Wulff, H, Ye, RD, Young, M, Zajac, J-M   +151 more
core   +4 more sources

Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D

Alimentary Pharmacology &Therapeutics, EarlyView.
Bulevirtide increases bile acid levels in most patients; however, changes in bile acids do not predict virological response or adverse events, nor do they reflect treatment adherence. After discontinuation of bulevirtide, bile acid levels rapidly decline.
Marlene Hintersteininger, Michael Schwarz, Philipp Schwabl, Lukas Hartl, Lorenz Balcar, Benedikt Silvester Hofer, Georg Kramer, Christian Sebesta, Paul Thöne, Patrik Attalla, Michael Gschwantler, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Mathias Jachs   +14 more
wiley   +1 more source

Fine-tuning of SIRT1 expression is essential to protect the liver from cholestatic liver disease [PDF]

, 2019
Cholestasis comprises aetiologically heterogeneous conditions characterized by accumulation of bile acids in the liver that actively contribute to liver damage.
Banales, Jesus M, Beraza, Naiara, Blokker, Britt A, Echeandia, Marta, Fuchs, Claudia, Galduroz, Mikel, Gutierrez-de Juan, Virginia, Halilbasic, Emina, Le Gall, Gwenaelle, Maijo, Monica, Martínez-Chantar, María Luz, Mato, José M, Milkiewicz, Malgorzata, Milkiewicz, Piotr, Müller, Michael, Patterson, Angela M, Philo, Mark, Rushbrook, Simon M, Schungel, Rebecca, Ten, Anna, Trauner, Michael, Varela-Rey, Marta   +21 more
core   +4 more sources

Hepatocyte TrkB Acts as a Gatekeeper Against MASH‐Related Liver Fibrosis by Suppressing the TGFβ/CCL2 Axis and Macrophage Infiltration

Cell Proliferation, EarlyView.
Hepatocyte TrkB is identified as a critical gatekeeper against MASH‐related fibrosis. Mechanistically, TrkB inhibits the TGFβ/SMAD3/FOS axis to suppress CCL2 secretion, thereby blocking pathogenic macrophage recruitment and ameliorating liver fibrosis.
Yueying Chen, Jiayi Wei, Shuxuan Li, Kefan Yin, Heming Wang, Yicheng Zhao, Shuqiang Weng, Xizhong Shen, Guangqi Song, Changfeng Zhu, Qunyan Yao, Ling Dong   +11 more
wiley   +1 more source

Hepatic bile acids and bile acid-related gene expression in pregnant and lactating rats [PDF]

, 2013
Background. Significant physiological changes occur during pregnancy and lactation. Intrahepatic cholestasis of pregnancy (ICP) is a liver disease closely related to disruption of bile acid homeostasis.
Dan Zhang, Hong M. Xie, Jie Liu, Qiong N. Zhu, Yuan F. Lu   +4 more
core   +1 more source